KR940006585A - Method for preparing core composition of oral omeprazole drug - Google Patents

Method for preparing core composition of oral omeprazole drug Download PDF

Info

Publication number
KR940006585A
KR940006585A KR1019920017403A KR920017403A KR940006585A KR 940006585 A KR940006585 A KR 940006585A KR 1019920017403 A KR1019920017403 A KR 1019920017403A KR 920017403 A KR920017403 A KR 920017403A KR 940006585 A KR940006585 A KR 940006585A
Authority
KR
South Korea
Prior art keywords
omeprazole
core composition
mol
oral
preparing
Prior art date
Application number
KR1019920017403A
Other languages
Korean (ko)
Other versions
KR960003605B1 (en
Inventor
정계종
전인구
인상환
Original Assignee
김생기
영진약품공업 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김생기, 영진약품공업 주식회사 filed Critical 김생기
Priority to KR1019920017403A priority Critical patent/KR960003605B1/en
Publication of KR940006585A publication Critical patent/KR940006585A/en
Application granted granted Critical
Publication of KR960003605B1 publication Critical patent/KR960003605B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Abstract

본 발명은 경구용 오메프라졸(omeprazole)약제의 코어 조성물을 제조하는 방법에 관한 것으로서, 더우기 상세하게는 난용성인 오메프라졸의 용출성과 안정성을 향상시키므로 경구용 장용성 약제의 코러 조성물로 유용하게 상용할 수 있도록 경구용 오메프라졸 코러 조성물을 제조하는 방법에 관한 것이다.The present invention relates to a method for preparing a core composition of oral omeprazole pharmaceuticals, and more particularly, to improve the dissolution and stability of poorly soluble omeprazole, oral so that it can be usefully used as a coral composition for oral enteric medicines. The present invention relates to a method for producing a omeprazole corlor composition.

Description

경구용 오메프라졸 약제의 코어 조성물을 제조하는 방법Method for preparing core composition of oral omeprazole drug

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (6)

오메프라졸을 유효성분으로 하고, 여기에 안정화 성분을 혼합시켜서 경구용 오메프라졸 약제의 코어 조성물을 제조함에 있어서, 유효성분인 오메프라졸에다 안정화 성분으로서 베타-시클로덱스트린 또는 그 유도체와 트로메타민 또는 수산화나트륨 중에서 선택된 알카리화합물을 첨가 혼합시켜서 고체분산체 또는 물리적 혼합물로 제조함을 특징으로 하는 경구용 오메프라졸 약제의 코어 조성물을 제조하는 방법.In preparing a core composition of an oral omeprazole drug by using omeprazole as an active ingredient and mixing a stabilizing ingredient, it is selected from beta-cyclodextrin or a derivative thereof and tromethamine or sodium hydroxide as an stabilizing ingredient in omeprazole as an active ingredient. A method for preparing the core composition of oral omeprazole pharmaceuticals, characterized in that the alkali compound is added and mixed to prepare a solid dispersion or physical mixture. 제1항에 있어서, 베타-시클로덱스트린 유도체로는 히드록시프로필 베타-시클로덱스트린을 사용함을 특징으로 하는 경구용 오메프라졸 코어 조성물의 제조방법.The method for preparing an oral omeprazole core composition according to claim 1, wherein hydroxypropyl beta-cyclodextrin is used as the beta-cyclodextrin derivative. 제1항에 있어서, 상기 베타-시클로덱스트린 또는 그 유도체는 오메프라졸 1몰에 대하여 0.5몰 내지 2몰로 첨가시킴을 특징으로 하는 경구용 오메프라졸 코어 조성물의 제조방법.The method of claim 1, wherein the beta-cyclodextrin or a derivative thereof is added in an amount of 0.5 mol to 2 mol based on 1 mol of omeprazole. 제1항에 있어서, 상기 알카리 화합물은 오메프라졸 1몰에 대하여 0.5몰에 대하여 0.5몰 내지 2몰로 첨가시킴을 특징으로 하는 경구용 오메프라졸 코어 조성물의 제조방법.The method of claim 1, wherein the alkali compound is added in an amount of 0.5 mol to 2 mol based on 0.5 mol based on 1 mol of omeprazole. 제1항에 있어서, 상기 코어 조성물의 고체분산체 또는 물리적 화합물에 추가적으로 산화마그네슘 및 탄산마스네슘 중에서 선택된 하나 또는 2가지 성분의 혼합물인 방습제를 혼합시키는 것을 특징으로 하는 경구용 오메프라졸 코어 조성물의 제조방법.The method for preparing an oral omeprazole core composition according to claim 1, wherein a desiccant, which is a mixture of one or two components selected from magnesium oxide and magnesium carbonate, is mixed with the solid dispersion or the physical compound of the core composition. . 제1항에 있어서, 상기 방습제는 상기 코어 조성물 1중량부에 대해 0.3중량부 내지 2중량부로 첨가하여 사용함을 특징으로 하는 경구용 오메프라졸 코어 조성물의 제조방법.The method of claim 1, wherein the desiccant is used in an amount of 0.3 parts by weight to 2 parts by weight based on 1 part by weight of the core composition. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019920017403A 1992-09-24 1992-09-24 Process for preparing oral omeprazole KR960003605B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019920017403A KR960003605B1 (en) 1992-09-24 1992-09-24 Process for preparing oral omeprazole

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019920017403A KR960003605B1 (en) 1992-09-24 1992-09-24 Process for preparing oral omeprazole

Publications (2)

Publication Number Publication Date
KR940006585A true KR940006585A (en) 1994-04-25
KR960003605B1 KR960003605B1 (en) 1996-03-20

Family

ID=19340036

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920017403A KR960003605B1 (en) 1992-09-24 1992-09-24 Process for preparing oral omeprazole

Country Status (1)

Country Link
KR (1) KR960003605B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110488A1 (en) * 2004-04-30 2005-11-24 Sk Chemicals Co., Ltd. Stable pharmaceutical composition containing benzimidazole derivatives and method of manufacturing the same

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102006777B1 (en) 2018-01-29 2019-10-08 주식회사 종근당 Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110488A1 (en) * 2004-04-30 2005-11-24 Sk Chemicals Co., Ltd. Stable pharmaceutical composition containing benzimidazole derivatives and method of manufacturing the same

Also Published As

Publication number Publication date
KR960003605B1 (en) 1996-03-20

Similar Documents

Publication Publication Date Title
NO971965D0 (en) A pharmaceutical composition containing a fusible carrier and process for its preparation
KR950007841A (en) Sustained-release drug formulations containing tramadol salts
KR850004392A (en) Method and composition of long-acting drug for oral administration
KR890004686A (en) Sustained release Etodolac
ES2157993T3 (en) BENZOILGUANIDINAS, ITS PREPARATION AND ITS USE IN MEDICINES.
KR880010758A (en) Sustained release preparations
KR890015745A (en) Pharmaceutical composition of pyricampum present in aqueous solution and preparation method thereof
DE69513254D1 (en) Compositions containing spirits
KR900005964A (en) Dispersible Formulations
KR850001693A (en) Method for preparing amosulolol hydrochloride long-acting formulation
IS7208A (en) Oral oral form of administration
NO870560L (en) NEW PHARMACEUTICAL PREPARATION.
KR940006585A (en) Method for preparing core composition of oral omeprazole drug
DE69428455D1 (en) METHOD FOR PRODUCING LOW-DOSE MEDICINAL PRODUCTS
CA2502582A1 (en) Pharmaceutical formulation of olanzapine
CO4830457A1 (en) EFFERVESCENT PREPARATIONS
PL114317B1 (en) Proces for preparing water solution of the complex of 3-chloro-4-/p-chlorophenoxy/-3,5-diiodosalicyloanilide with polyvinyl pyrrolidone
KR930021206A (en) Cytarabine Oxphosphate Hard Capsule
YU72802A (en) Pharmaceutical compositions containing oligosaccharides and preparation thereof
KR930012018A (en) Pharmaceutical composition
HK1055675A1 (en) Method for stabilizing a pharmaceutical preparation
CA2534259A1 (en) Glycyrrhizin high-concentration preparation
JPH0669948B2 (en) Lozenges
KR900015732A (en) Oral preparations
WO2000051603A3 (en) Compositions of remifentanil

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030320

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee